Collegium Pharmaceutical：镇痛业务现金流正助力多动症业务估值重塑 (NASDAQ:COLL)
· seekingalpha.com
Collegium Pharma (COLL) 正通过 AZSTARYS 转型为中枢神经系统 (CNS)/ADHD 增长平台，目标指向 2026 年营收及 EBITDA 上行空间；目前股价似乎被低估——点击阅读全文。
I have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and in...